<DOC>
	<DOCNO>NCT00468611</DOCNO>
	<brief_summary>This study ass efficacy safety MBP8298 compare placebo subject Secondary Progressive Multiple Sclerosis ( SPMS )</brief_summary>
	<brief_title>Efficacy Safety MBP8298 Subjects With Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>Male female subject , 1865 year age diagnosis SPMS HLA DR2 and/or DR4 positive Absence relapse 3 month prior baseline EDSS 3.0 6.5 Therapy Betainterferon , glatiramer acetate within 3 month mitoxantrone , cyclophosphamide , methotrexate , azathioprine immune modulate immunosuppressive drug within 6 month baseline Treatment Tysabri within 2 year baseline Females breast feeding , pregnant ( pregnancy test baseline ) use medically approve method contraception regularly Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Secondary Progressive Multiple Sclerosis</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>